MET and cancer: In a limited number of cases, accounting for 2–3% of total cancers (COSMIC database: www.sanger.ac.uk, accessed on 10 September 2021), MET is the driver gene of malignancy, and this status (MET addiction) is strictly related to the presence of MET gene lesions [3].